25 XP   0   0   10

Grifols SA ADR
Buy, Hold or Sell?

Let's analyse Grifols together

PenkeI guess you are interested in Grifols SA ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Grifols SA ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Grifols SA ADR

I send you an email if I find something interesting about Grifols SA ADR.

Quick analysis of Grifols (30 sec.)










What can you expect buying and holding a share of Grifols? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
70.0%

What is your share worth?

Current worth
$6.38
Expected worth in 1 year
$6.00
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$-0.38
Return On Investment
-7.8%

For what price can you sell your share?

Current Price per Share
$4.84
Expected price per share
$4.4 - $8.7
How sure are you?
50%

1. Valuation of Grifols (5 min.)




Live pricePrice per Share (EOD)

$4.84

Intrinsic Value Per Share

$-0.51 - $3.26

Total Value Per Share

$5.87 - $9.64

2. Growth of Grifols (5 min.)




Is Grifols growing?

Current yearPrevious yearGrowGrow %
How rich?$8.6b$9b-$202m-2.3%

How much money is Grifols making?

Current yearPrevious yearGrowGrow %
Making money$62.8m$39.1m$23.6m37.7%
Net Profit Margin3.4%2.3%--

How much money comes from the company's main activities?

3. Financial Health of Grifols (5 min.)




What can you expect buying and holding a share of Grifols? (5 min.)

Welcome investor! Grifols's management wants to use your money to grow the business. In return you get a share of Grifols.

What can you expect buying and holding a share of Grifols?

First you should know what it really means to hold a share of Grifols. And how you can make/lose money.

Speculation

The Price per Share of Grifols is $4.84. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Grifols.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Grifols, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.38. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Grifols.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.040.9%0.051.0%0.030.6%0.071.4%0.091.8%
Usd Book Value Change Per Share0.000.0%-0.09-1.9%0.234.7%0.132.7%0.122.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.040.9%0.051.1%
Usd Total Gains Per Share0.000.0%-0.09-1.9%0.234.7%0.183.6%0.173.5%
Usd Price Per Share4.52-6.53-6.13-10.87-11.89-
Price to Earnings Ratio25.26-35.37--4.19-19.30-25.18-
Price-to-Total Gains Ratio-9.78-8.32-35.49-75.06-
Price to Book Ratio0.71-1.00-0.92-1.99-3.58-
Price-to-Total Gains Ratio-9.78-8.32-35.49-75.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.84
Number of shares206
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.090.13
Usd Total Gains Per Share-0.090.18
Gains per Quarter (206 shares)-19.3936.26
Gains per Year (206 shares)-77.55145.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-78-8836109135
20-155-16671219280
30-233-244107328425
40-310-322143438570
50-388-400178547715
60-465-478214656860
70-543-5562507661005
80-620-6342858751150
90-698-7123219851295
100-776-79035610941440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%9.03.00.075.0%17.03.00.085.0%37.03.00.092.5%51.04.00.092.7%
Book Value Change Per Share1.02.01.025.0%6.03.03.050.0%11.04.05.055.0%25.05.010.062.5%36.05.014.065.5%
Dividend per Share0.00.04.00.0%4.00.08.033.3%12.00.08.060.0%28.00.012.070.0%35.00.020.063.6%
Total Gains per Share1.02.01.025.0%6.03.03.050.0%13.04.03.065.0%32.05.03.080.0%45.05.05.081.8%

Fundamentals of Grifols

About Grifols SA ADR

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Fundamental data was last updated by Penke on 2024-05-16 17:52:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Grifols SA ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Grifols earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 3.2% means that $0.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Grifols SA ADR:

  • The MRQ is 3.2%. The company is making a profit. +1
  • The TTM is 3.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ3.2%TTM3.4%-0.3%
TTM3.4%YOY2.3%+1.1%
TTM3.4%5Y6.8%-3.4%
5Y6.8%10Y10.5%-3.6%
1.1.2. Return on Assets

Shows how efficient Grifols is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • 0.3% Return on Assets means that Grifols generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Grifols SA ADR:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM0.3%0.0%
TTM0.3%YOY0.2%+0.1%
TTM0.3%5Y0.6%-0.3%
5Y0.6%10Y1.0%-0.4%
1.1.3. Return on Equity

Shows how efficient Grifols is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • 1.0% Return on Equity means Grifols generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Grifols SA ADR:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.0%0.0%
TTM1.0%YOY3.4%-2.4%
TTM1.0%5Y2.4%-1.4%
5Y2.4%10Y3.3%-1.0%

1.2. Operating Efficiency of Grifols SA ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Grifols is operating .

  • Measures how much profit Grifols makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 12.6% means the company generated $0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Grifols SA ADR:

  • The MRQ is 12.6%. The company is operating less efficient.
  • The TTM is 14.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ12.6%TTM14.0%-1.4%
TTM14.0%YOY12.7%+1.3%
TTM14.0%5Y15.2%-1.1%
5Y15.2%10Y18.7%-3.5%
1.2.2. Operating Ratio

Measures how efficient Grifols is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are $0.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Grifols SA ADR:

  • The MRQ is 0.874. The company is less efficient in keeping operating costs low.
  • The TTM is 0.863. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.874TTM0.863+0.011
TTM0.863YOY1.052-0.189
TTM0.8635Y0.840+0.023
5Y0.84010Y0.805+0.034

1.3. Liquidity of Grifols SA ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Grifols is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 2.79 means the company has $2.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Grifols SA ADR:

  • The MRQ is 2.786. The company is able to pay all its short-term debts. +1
  • The TTM is 2.652. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.786TTM2.652+0.134
TTM2.652YOY2.435+0.217
TTM2.6525Y2.524+0.128
5Y2.52410Y2.717-0.192
1.3.2. Quick Ratio

Measures if Grifols is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.63 means the company can pay off $0.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Grifols SA ADR:

  • The MRQ is 0.629. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.695. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.629TTM0.695-0.066
TTM0.695YOY0.720-0.025
TTM0.6955Y1.112-0.417
5Y1.11210Y1.249-0.137

1.4. Solvency of Grifols SA ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Grifols assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Grifols to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.63 means that Grifols assets are financed with 62.8% credit (debt) and the remaining percentage (100% - 62.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Grifols SA ADR:

  • The MRQ is 0.628. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.621. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.628TTM0.621+0.007
TTM0.621YOY0.608+0.013
TTM0.6215Y0.597+0.024
5Y0.59710Y0.627-0.030
1.4.2. Debt to Equity Ratio

Measures if Grifols is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 231.1% means that company has $2.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Grifols SA ADR:

  • The MRQ is 2.311. The company is just not able to pay all its debts with equity.
  • The TTM is 2.270. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.311TTM2.270+0.042
TTM2.270YOY10.268-7.998
TTM2.2705Y3.616-1.346
5Y3.61610Y2.783+0.833

2. Market Valuation of Grifols SA ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Grifols generates.

  • Above 15 is considered overpriced but always compare Grifols to the Drug Manufacturers - General industry mean.
  • A PE ratio of 25.26 means the investor is paying $25.26 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Grifols SA ADR:

  • The EOD is 27.051. Based on the earnings, the company is overpriced. -1
  • The MRQ is 25.262. Based on the earnings, the company is overpriced. -1
  • The TTM is 35.370. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD27.051MRQ25.262+1.788
MRQ25.262TTM35.370-10.107
TTM35.370YOY-4.186+39.556
TTM35.3705Y19.298+16.072
5Y19.29810Y25.178-5.880
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Grifols SA ADR:

  • The EOD is 28.430. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 26.550. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 18.432. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD28.430MRQ26.550+1.880
MRQ26.550TTM18.432+8.118
TTM18.432YOY-17.344+35.776
TTM18.4325Y23.785-5.353
5Y23.78510Y22.787+0.998
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Grifols is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.71 means the investor is paying $0.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Grifols SA ADR:

  • The EOD is 0.759. Based on the equity, the company is cheap. +2
  • The MRQ is 0.708. Based on the equity, the company is cheap. +2
  • The TTM is 0.999. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.759MRQ0.708+0.050
MRQ0.708TTM0.999-0.291
TTM0.999YOY0.925+0.075
TTM0.9995Y1.994-0.994
5Y1.99410Y3.576-1.582
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Grifols SA ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.0940%0.228-100%0.133-100%0.117-100%
Book Value Per Share--6.3806.544-3%6.654-4%5.828+9%4.285+49%
Current Ratio--2.7862.652+5%2.435+14%2.524+10%2.717+3%
Debt To Asset Ratio--0.6280.621+1%0.608+3%0.597+5%0.627+0%
Debt To Equity Ratio--2.3112.270+2%10.268-77%3.616-36%2.783-17%
Dividend Per Share----0%0.000-100%0.043-100%0.053-100%
Eps--0.0450.046-3%0.028+57%0.070-36%0.089-50%
Free Cash Flow Per Share--0.0430.024+76%-0.095+323%0.059-27%0.088-52%
Free Cash Flow To Equity Per Share--0.0800.065+23%-0.187+334%0.114-30%0.100-20%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.258--------
Intrinsic Value_10Y_min---0.508--------
Intrinsic Value_1Y_max--0.349--------
Intrinsic Value_1Y_min---0.018--------
Intrinsic Value_3Y_max--1.031--------
Intrinsic Value_3Y_min---0.082--------
Intrinsic Value_5Y_max--1.693--------
Intrinsic Value_5Y_min---0.178--------
Market Cap6573591045.120+7%6138973455.3608873329275.936-31%8405365662.576-27%14873845597.007-59%16314136530.231-62%
Net Profit Margin--0.0320.034-7%0.023+37%0.068-54%0.105-70%
Operating Margin--0.1260.140-10%0.127-1%0.152-17%0.187-33%
Operating Ratio--0.8740.863+1%1.052-17%0.840+4%0.805+9%
Pb Ratio0.759+7%0.7080.999-29%0.925-23%1.994-64%3.576-80%
Pe Ratio27.051+7%25.26235.370-29%-4.186+117%19.298+31%25.178+0%
Price Per Share4.840+7%4.5206.533-31%6.134-26%10.874-58%11.894-62%
Price To Free Cash Flow Ratio28.430+7%26.55018.432+44%-17.344+165%23.785+12%22.787+17%
Quick Ratio--0.6290.695-10%0.720-13%1.112-43%1.249-50%
Return On Assets--0.0030.003-3%0.002+53%0.006-55%0.010-74%
Return On Equity--0.0100.010-2%0.034-71%0.024-59%0.033-71%
Total Gains Per Share----0.0940%0.228-100%0.176-100%0.171-100%
Usd Book Value--8665126820.0008887462578.750-3%9089500971.250-5%7954186049.250+9%5857837205.500+48%
Usd Book Value Change Per Share----0.0940%0.228-100%0.133-100%0.117-100%
Usd Book Value Per Share--6.3806.544-3%6.654-4%5.828+9%4.285+49%
Usd Dividend Per Share----0%0.000-100%0.043-100%0.053-100%
Usd Eps--0.0450.046-3%0.028+57%0.070-36%0.089-50%
Usd Free Cash Flow--57805545.00032801177.500+76%-97139236.250+268%72048123.000-20%114601307.625-50%
Usd Free Cash Flow Per Share--0.0430.024+76%-0.095+323%0.059-27%0.088-52%
Usd Free Cash Flow To Equity Per Share--0.0800.065+23%-0.187+334%0.114-30%0.100-20%
Usd Market Cap6573591045.120+7%6138973455.3608873329275.936-31%8405365662.576-27%14873845597.007-59%16314136530.231-62%
Usd Price Per Share4.840+7%4.5206.533-31%6.134-26%10.874-58%11.894-62%
Usd Profit--60752405.00062811735.000-3%39160633.750+55%100425267.250-40%129296493.375-53%
Usd Revenue--1919960665.0001844510307.500+4%1719570658.750+12%1494409614.250+28%1310415015.875+47%
Usd Total Gains Per Share----0.0940%0.228-100%0.176-100%0.171-100%
 EOD+3 -4MRQTTM+10 -18YOY+16 -185Y+8 -2610Y+8 -26

3.2. Fundamental Score

Let's check the fundamental score of Grifols SA ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1527.051
Price to Book Ratio (EOD)Between0-10.759
Net Profit Margin (MRQ)Greater than00.032
Operating Margin (MRQ)Greater than00.126
Quick Ratio (MRQ)Greater than10.629
Current Ratio (MRQ)Greater than12.786
Debt to Asset Ratio (MRQ)Less than10.628
Debt to Equity Ratio (MRQ)Less than12.311
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.003
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Grifols SA ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.429
Ma 20Greater thanMa 504.963
Ma 50Greater thanMa 1004.677
Ma 100Greater thanMa 2005.133
OpenGreater thanClose4.840
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets21,454,670
Total Liabilities13,468,378
Total Stockholder Equity5,827,166
 As reported
Total Liabilities 13,468,378
Total Stockholder Equity+ 5,827,166
Total Assets = 21,454,670

Assets

Total Assets21,454,670
Total Current Assets6,451,905
Long-term Assets15,002,765
Total Current Assets
Cash And Cash Equivalents 529,577
Short-term Investments 116,143
Net Receivables 810,860
Inventory 3,459,277
Other Current Assets 1,652,191
Total Current Assets  (as reported)6,451,905
Total Current Assets  (calculated)6,568,048
+/- 116,143
Long-term Assets
Property Plant Equipment 4,192,363
Goodwill 6,802,127
Intangible Assets 2,832,196
Long-term Assets Other 154,394
Long-term Assets  (as reported)15,002,765
Long-term Assets  (calculated)13,981,080
+/- 1,021,685

Liabilities & Shareholders' Equity

Total Current Liabilities2,315,604
Long-term Liabilities11,152,774
Total Stockholder Equity5,827,166
Total Current Liabilities
Short-term Debt 897,915
Accounts payable 813,114
Other Current Liabilities 565,382
Total Current Liabilities  (as reported)2,315,604
Total Current Liabilities  (calculated)2,276,411
+/- 39,193
Long-term Liabilities
Long-term Liabilities  (as reported)11,152,774
Long-term Liabilities  (calculated)0
+/- 11,152,774
Total Stockholder Equity
Common Stock119,604
Retained Earnings 59,315
Accumulated Other Comprehensive Income 4,949,582
Other Stockholders Equity 698,665
Total Stockholder Equity (as reported)5,827,166
Total Stockholder Equity (calculated)5,827,166
+/-0
Other
Cash and Short Term Investments 529,577
Common Stock Shares Outstanding 679,092
Current Deferred Revenue39,193
Liabilities and Stockholders Equity 21,454,670
Net Debt 9,587,862
Short Long Term Debt Total 10,117,439



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-30
> Total Assets 
0
1,888,982
1,888,982
5,344,219
5,486,724
5,807,718
5,543,025
5,912,417
5,837,321
5,627,474
5,627,474
5,846,159
5,711,151
5,841,036
5,841,036
7,276,096
8,102,746
8,449,749
8,449,749
9,095,358
9,178,563
9,601,715
9,601,715
9,539,658
9,567,865
10,129,772
10,129,772
11,116,979
11,009,939
10,920,264
10,920,264
11,433,619
11,779,675
12,477,046
12,477,046
13,323,775
14,036,984
15,542,611
15,542,611
15,597,511
15,646,913
15,274,776
15,274,776
16,213,049
19,233,835
0
19,233,835
21,039,074
21,533,977
21,350,830
21,533,977
21,432,744
22,064,498
21,454,670
21,454,670
21,454,67021,454,67022,064,49821,432,74421,533,97721,350,83021,533,97721,039,07419,233,835019,233,83516,213,04915,274,77615,274,77615,646,91315,597,51115,542,61115,542,61114,036,98413,323,77512,477,04612,477,04611,779,67511,433,61910,920,26410,920,26411,009,93911,116,97910,129,77210,129,7729,567,8659,539,6589,601,7159,601,7159,178,5639,095,3588,449,7498,449,7498,102,7467,276,0965,841,0365,841,0365,711,1515,846,1595,627,4745,627,4745,837,3215,912,4175,543,0255,807,7185,486,7245,344,2191,888,9821,888,9820
   > Total Current Assets 
0
1,144,082
1,144,082
2,109,666
1,679,898
1,929,215
1,772,920
1,896,772
1,921,424
1,934,564
1,934,564
2,039,313
1,982,701
2,139,660
2,139,660
2,412,406
2,707,671
2,913,122
2,913,122
2,751,887
2,841,230
3,089,472
3,089,472
2,920,719
2,953,073
3,122,514
3,122,514
2,851,032
2,915,714
2,945,316
2,945,316
2,947,373
3,024,376
3,483,251
3,483,251
3,424,363
3,659,798
5,362,184
5,362,184
3,554,170
3,643,616
3,164,954
3,164,954
3,239,500
5,510,280
5,510,280
5,510,280
4,432,773
4,653,587
4,708,888
4,653,587
4,804,772
5,015,368
6,451,905
6,451,905
6,451,9056,451,9055,015,3684,804,7724,653,5874,708,8884,653,5874,432,7735,510,2805,510,2805,510,2803,239,5003,164,9543,164,9543,643,6163,554,1705,362,1845,362,1843,659,7983,424,3633,483,2513,483,2513,024,3762,947,3732,945,3162,945,3162,915,7142,851,0323,122,5143,122,5142,953,0732,920,7193,089,4723,089,4722,841,2302,751,8872,913,1222,913,1222,707,6712,412,4062,139,6602,139,6601,982,7012,039,3131,934,5641,934,5641,921,4241,896,7721,772,9201,929,2151,679,8982,109,6661,144,0821,144,0820
       Cash And Cash Equivalents 
0
239,649
239,649
583,792
162,615
340,586
164,968
314,640
400,600
473,327
473,327
479,157
488,277
708,777
708,777
736,904
917,704
1,079,146
1,079,146
788,734
891,848
1,142,500
1,142,500
807,019
900,461
895,009
895,009
750,218
815,115
886,521
886,521
668,499
582,008
1,033,792
1,033,792
553,697
792,134
741,982
741,982
878,406
1,033,195
579,647
579,647
397,864
655,493
0
655,493
525,094
547,979
425,655
547,979
523,352
484,226
529,577
529,577
529,577529,577484,226523,352547,979425,655547,979525,094655,4930655,493397,864579,647579,6471,033,195878,406741,982741,982792,134553,6971,033,7921,033,792582,008668,499886,521886,521815,115750,218895,009895,009900,461807,0191,142,5001,142,500891,848788,7341,079,1461,079,146917,704736,904708,777708,777488,277479,157473,327473,327400,600314,640164,968340,586162,615583,792239,649239,6490
       Short-term Investments 
0
12,946
12,946
19,254
24,543
16,904
29,167
26,943
795
0
192
757
527
0
232
350
368
0
476
1,177
779
0
509
1,983
1,779
957
957
868
11,381
525
702
21,059
51,392
822
53,965
169,434
2,764
1,727,429
1,727,429
12,317
12,288
10,861
10,861
9,681
2,026,430
0
2,026,430
36,058
30,986
30,627
30,627
33,883
59,410
116,143
116,143
116,143116,14359,41033,88330,62730,62730,98636,0582,026,43002,026,4309,68110,86110,86112,28812,3171,727,4291,727,4292,764169,43453,96582251,39221,05970252511,3818689579571,7791,98350907791,17747603683502320527757192079526,94329,16716,90424,54319,25412,94612,9460
       Net Receivables 
0
282,994
282,994
495,450
482,080
531,989
556,479
506,722
479,529
441,788
441,788
553,504
489,891
462,655
462,655
624,488
623,536
608,328
608,328
594,071
552,286
477,803
477,803
554,882
475,214
528,518
528,518
478,038
471,385
385,265
385,265
415,744
462,839
401,573
401,573
458,962
464,280
470,495
470,495
534,973
568,294
504,200
504,200
644,698
434,136
495,476
434,136
772,978
754,820
884,234
754,820
865,708
908,030
810,860
810,860
810,860810,860908,030865,708754,820884,234754,820772,978434,136495,476434,136644,698504,200504,200568,294534,973470,495470,495464,280458,962401,573401,573462,839415,744385,265385,265471,385478,038528,518528,518475,214554,882477,803477,803552,286594,071608,328608,328623,536624,488462,655462,655489,891553,504441,788441,788479,529506,722556,479531,989482,080495,450282,994282,9940
       Other Current Assets 
0
80,628
80,628
13,344
13,636
9,395
26,128
15,514
15,708
20,805
20,805
15,663
18,729
21,315
21,315
19,242
22,119
23,669
23,669
25,190
36,834
31,091
31,091
25,968
31,117
48,324
48,324
26,122
23,618
32,354
32,354
35,306
63,942
42,344
42,344
36,507
73,450
58,111
58,111
43,370
43,763
51,750
51,750
62,864
134,867
70,289
134,867
74,306
118,445
121,946
81,814
64,381
77,019
1,652,191
1,652,191
1,652,1911,652,19177,01964,38181,814121,946118,44574,306134,86770,289134,86762,86451,75051,75043,76343,37058,11158,11173,45036,50742,34442,34463,94235,30632,35432,35423,61826,12248,32448,32431,11725,96831,09131,09136,83425,19023,66923,66922,11919,24221,31521,31518,72915,66320,80520,80515,70815,51426,1289,39513,63613,34480,62880,6280
   > Long-term Assets 
0
744,900
744,900
3,234,553
3,806,826
3,878,503
3,770,105
4,015,645
3,915,897
3,692,910
3,692,910
3,806,846
3,728,450
3,701,376
3,701,376
4,863,690
5,395,075
5,536,627
5,536,627
6,343,471
6,337,333
6,512,243
6,512,243
6,618,939
6,614,792
7,007,258
7,007,258
8,265,947
8,094,225
7,974,948
7,974,948
8,486,246
8,755,299
8,993,795
8,993,795
9,899,412
10,377,186
10,180,427
10,180,427
12,043,341
12,003,297
12,109,822
12,109,822
12,973,549
13,723,555
0
13,723,555
16,606,301
14,949,982
16,641,942
16,880,390
16,627,972
17,049,130
15,002,765
15,002,765
15,002,76515,002,76517,049,13016,627,97216,880,39016,641,94214,949,98216,606,30113,723,555013,723,55512,973,54912,109,82212,109,82212,003,29712,043,34110,180,42710,180,42710,377,1869,899,4128,993,7958,993,7958,755,2998,486,2467,974,9487,974,9488,094,2258,265,9477,007,2587,007,2586,614,7926,618,9396,512,2436,512,2436,337,3336,343,4715,536,6275,536,6275,395,0754,863,6903,701,3763,701,3763,728,4503,806,8463,692,9103,692,9103,915,8974,015,6453,770,1053,878,5033,806,8263,234,553744,900744,9000
       Property Plant Equipment 
0
434,131
434,131
639,735
868,331
775,869
772,513
823,251
809,060
810,107
810,107
840,880
826,604
840,238
840,238
999,201
1,077,813
1,147,782
1,147,782
1,559,928
1,582,389
1,644,402
1,644,402
1,659,780
1,680,447
1,809,852
1,809,852
1,775,907
1,740,630
1,760,053
1,760,053
1,819,289
1,868,809
1,951,983
1,951,983
2,680,255
2,112,661
2,863,403
2,863,403
2,911,500
2,173,983
3,002,803
3,002,803
3,135,099
3,343,154
3,343,154
3,343,154
4,227,930
4,168,489
3,220,428
4,168,489
3,225,684
3,278,650
4,192,363
4,192,363
4,192,3634,192,3633,278,6503,225,6844,168,4893,220,4284,168,4894,227,9303,343,1543,343,1543,343,1543,135,0993,002,8033,002,8032,173,9832,911,5002,863,4032,863,4032,112,6612,680,2551,951,9831,951,9831,868,8091,819,2891,760,0531,760,0531,740,6301,775,9071,809,8521,809,8521,680,4471,659,7801,644,4021,644,4021,582,3891,559,9281,147,7821,147,7821,077,813999,201840,238840,238826,604840,880810,107810,107809,060823,251772,513775,869868,331639,735434,131434,1310
       Goodwill 
0
189,448
189,448
0
0
1,895,101
1,836,684
1,950,389
1,905,820
1,869,899
1,869,899
1,937,064
1,879,973
1,829,141
1,829,141
2,779,267
3,089,570
3,174,732
3,174,732
3,440,974
3,434,748
3,532,359
3,532,359
3,464,745
3,446,734
3,643,995
3,643,995
5,023,903
0
4,590,498
4,590,498
4,993,142
0
5,209,230
5,209,230
5,416,606
0
5,507,063
5,507,063
5,501,972
0
5,332,271
5,332,271
5,988,765
6,228,901
0
6,228,901
7,847,911
7,011,909
7,011,909
7,011,909
6,898,821
0
6,802,127
6,802,127
6,802,1276,802,12706,898,8217,011,9097,011,9097,011,9097,847,9116,228,90106,228,9015,988,7655,332,2715,332,27105,501,9725,507,0635,507,06305,416,6065,209,2305,209,23004,993,1424,590,4984,590,49805,023,9033,643,9953,643,9953,446,7343,464,7453,532,3593,532,3593,434,7483,440,9743,174,7323,174,7323,089,5702,779,2671,829,1411,829,1411,879,9731,937,0641,869,8991,869,8991,905,8201,950,3891,836,6841,895,10100189,448189,4480
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
232,421
307,941
268,879
295,103
193,750
330,171
228,262
173,862
228,820
366,980
267,653
264,308
143,984
2,089,839
2,071,069
2,039,351
2,067,177
2,129,789
2,136,964
0
0
0
2,554,608
0
2,443,078
0
2,536,044
2,597,295
565,105
0
0565,1052,597,2952,536,04402,443,07802,554,6080002,136,9642,129,7892,067,1772,039,3512,071,0692,089,839143,984264,308267,653366,980228,820173,862228,262330,171193,750295,103268,879307,941232,4210000000000000000000000000
       Intangible Assets 
0
78,299
78,299
0
0
1,008,307
971,901
1,038,977
1,000,746
969,095
969,095
974,645
949,631
946,435
946,435
984,153
1,048,567
1,068,361
1,068,361
1,149,060
1,138,643
1,161,572
1,161,572
1,139,126
1,130,970
1,195,302
1,195,302
1,101,789
5,972,107
1,269,342
1,269,342
1,342,527
6,580,700
1,385,537
1,385,537
1,417,377
7,880,443
1,433,534
1,433,534
1,433,768
7,663,567
1,557,650
1,557,650
1,570,576
1,003,710
0
1,003,710
1,736,913
1,326,506
10,646,785
2,949,147
2,880,245
10,876,233
2,832,196
2,832,196
2,832,1962,832,19610,876,2332,880,2452,949,14710,646,7851,326,5061,736,9131,003,71001,003,7101,570,5761,557,6501,557,6507,663,5671,433,7681,433,5341,433,5347,880,4431,417,3771,385,5371,385,5376,580,7001,342,5271,269,3421,269,3425,972,1071,101,7891,195,3021,195,3021,130,9701,139,1261,161,5721,161,5721,138,6431,149,0601,068,3611,068,3611,048,567984,153946,435946,435949,631974,645969,095969,0951,000,7461,038,977971,9011,008,3070078,29978,2990
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196,308
77,582
95,469
86,385
245,559
61,082
103,026
49,049
505,430
152,044
224,468
119,774
564,251
131,545
254,449
126,396
812,555
142,002
232,391
882,614
882,614
15,840
344,972
1,930,408
197,837
0
0
0
0
0
00000197,8371,930,408344,97215,840882,614882,614232,391142,002812,555126,396254,449131,545564,251119,774224,468152,044505,43049,049103,02661,082245,55986,38595,46977,582196,3080000000000000000000000000
> Total Liabilities 
0
1,181,592
1,181,592
3,830,625
3,888,114
4,142,724
3,858,297
4,074,583
3,983,199
3,746,733
3,746,733
3,901,399
3,741,961
3,733,832
3,733,832
5,038,472
5,563,079
5,786,861
5,786,861
6,021,473
5,975,546
6,300,325
6,300,325
6,127,307
6,035,427
6,401,794
6,401,794
7,532,149
7,421,824
7,286,299
7,286,299
7,462,375
7,632,305
7,780,442
7,780,442
8,437,956
8,745,110
8,696,843
8,696,843
8,556,735
8,538,992
8,554,721
8,554,721
9,275,958
11,916,737
0
11,916,737
12,619,686
13,076,433
13,175,625
13,076,433
13,209,179
13,495,808
13,468,378
13,468,378
13,468,37813,468,37813,495,80813,209,17913,076,43313,175,62513,076,43312,619,68611,916,737011,916,7379,275,9588,554,7218,554,7218,538,9928,556,7358,696,8438,696,8438,745,1108,437,9567,780,4427,780,4427,632,3057,462,3757,286,2997,286,2997,421,8247,532,1496,401,7946,401,7946,035,4276,127,3076,300,3256,300,3255,975,5466,021,4735,786,8615,786,8615,563,0795,038,4723,733,8323,733,8323,741,9613,901,3993,746,7333,746,7333,983,1994,074,5833,858,2974,142,7243,888,1143,830,6251,181,5921,181,5920
   > Total Current Liabilities 
0
423,126
423,126
962,930
555,483
646,077
660,812
677,890
641,208
592,865
592,865
742,411
656,592
715,296
715,296
796,993
985,538
1,079,711
1,079,711
1,005,317
975,446
1,053,006
1,053,006
975,191
925,678
1,071,763
1,071,763
900,321
952,067
977,987
977,987
1,015,690
1,086,420
1,257,321
1,257,321
1,276,459
1,394,814
1,366,558
1,366,558
1,240,627
1,244,510
1,335,138
1,335,138
1,921,478
3,474,312
3,474,312
3,474,312
1,656,330
1,955,847
2,041,284
1,955,847
1,876,984
2,025,059
2,315,604
2,315,604
2,315,6042,315,6042,025,0591,876,9841,955,8472,041,2841,955,8471,656,3303,474,3123,474,3123,474,3121,921,4781,335,1381,335,1381,244,5101,240,6271,366,5581,366,5581,394,8141,276,4591,257,3211,257,3211,086,4201,015,690977,987977,987952,067900,3211,071,7631,071,763925,678975,1911,053,0061,053,006975,4461,005,3171,079,7111,079,711985,538796,993715,296715,296656,592742,411592,865592,865641,208677,890660,812646,077555,483962,930423,126423,1260
       Short-term Debt 
0
191,635
191,635
509,726
121,650
147,789
184,689
208,115
184,444
192,003
192,003
234,971
228,189
251,389
251,389
175,853
175,730
165,860
165,860
169,738
200,192
186,797
186,797
191,939
204,761
203,944
203,944
129,333
170,557
133,067
133,067
192,648
247,568
268,199
268,199
328,564
415,426
320,802
320,802
260,059
319,916
319,571
319,571
899,517
2,349,774
0
2,349,774
401,283
0
761,319
681,273
733,269
757,246
897,915
897,915
897,915897,915757,246733,269681,273761,3190401,2832,349,77402,349,774899,517319,571319,571319,916260,059320,802320,802415,426328,564268,199268,199247,568192,648133,067133,067170,557129,333203,944203,944204,761191,939186,797186,797200,192169,738165,860165,860175,730175,853251,389251,389228,189234,971192,003192,003184,444208,115184,689147,789121,650509,726191,635191,6350
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,905,583
6,491,862
6,148,992
170,557
96,569
174,405
188,757
180,469
257,772
414,895
289,133
415,426
276,397
0
215,445
0
276,929
0
854,202
0
0
0
338,987
0
578,917
0
0
0
790,814
0
0790,814000578,9170338,987000854,2020276,9290215,4450276,397415,426289,133414,895257,772180,469188,757174,40596,569170,5576,148,9926,491,8624,905,5830000000000000000000000000
       Accounts payable 
0
160,678
160,678
292,011
0
280,722
302,285
277,635
268,966
228,405
228,405
241,198
241,825
273,621
273,621
370,755
393,078
439,631
439,631
367,794
351,816
409,986
409,986
400,542
390,979
461,073
461,073
394,821
0
423,096
423,096
427,194
0
561,883
561,883
536,743
0
581,882
581,882
551,905
0
601,618
601,618
580,247
628,992
628,992
628,992
701,158
731,918
731,918
731,918
708,970
0
813,114
813,114
813,114813,1140708,970731,918731,918731,918701,158628,992628,992628,992580,247601,618601,6180551,905581,882581,8820536,743561,883561,8830427,194423,096423,0960394,821461,073461,073390,979400,542409,986409,986351,816367,794439,631439,631393,078370,755273,621273,621241,825241,198228,405228,405268,966277,635302,285280,7220292,011160,678160,6780
       Other Current Liabilities 
0
18,236
18,236
98,138
433,833
101,993
67,327
71,135
89,725
6,243
6,243
80,783
97,407
182,823
182,823
796,993
154,709
453,847
453,847
157,489
187,098
447,032
447,032
975,191
137,513
399,742
399,742
147,962
781,510
407,595
407,595
151,038
838,852
411,714
411,714
163,612
979,388
453,236
453,236
217,385
924,594
389,969
389,969
412,179
495,546
123,594
495,546
553,889
1,223,929
1,279,965
504,822
1,143,715
1,267,813
565,382
565,382
565,382565,3821,267,8131,143,715504,8221,279,9651,223,929553,889495,546123,594495,546412,179389,969389,969924,594217,385453,236453,236979,388163,612411,714411,714838,852151,038407,595407,595781,510147,962399,742399,742137,513975,191447,032447,032187,098157,489453,847453,847154,709796,993182,823182,82397,40780,7836,2436,24389,72571,13567,327101,993433,83398,13818,23618,2360
   > Long-term Liabilities 
0
758,466
758,466
2,867,695
3,332,631
3,496,647
3,197,485
3,396,693
3,341,991
3,153,868
3,153,868
3,158,988
3,085,369
3,018,536
3,018,536
4,241,479
4,577,541
4,707,150
4,707,150
5,016,156
5,000,100
5,247,319
5,247,319
5,152,116
5,109,749
5,330,031
5,330,031
6,631,828
6,469,757
6,308,312
6,308,312
6,446,685
6,545,885
6,523,121
6,523,121
7,161,497
7,350,296
7,330,285
7,330,285
7,316,108
7,294,482
7,219,583
7,219,583
7,354,480
8,442,425
0
8,442,425
10,963,356
8,154,264
11,134,341
11,120,586
11,332,195
11,470,749
11,152,774
11,152,774
11,152,77411,152,77411,470,74911,332,19511,120,58611,134,3418,154,26410,963,3568,442,42508,442,4257,354,4807,219,5837,219,5837,294,4827,316,1087,330,2857,330,2857,350,2967,161,4976,523,1216,523,1216,545,8856,446,6856,308,3126,308,3126,469,7576,631,8285,330,0315,330,0315,109,7495,152,1165,247,3195,247,3195,000,1005,016,1564,707,1504,707,1504,577,5414,241,4793,018,5363,018,5363,085,3693,158,9883,153,8683,153,8683,341,9913,396,6933,197,4853,496,6473,332,6312,867,695758,466758,4660
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
648,935
613,706
612,169
580,302
321,692
389,914
490,800
313,476
502,613
541,589
499,437
446,719
544,198
492,373
533,082
566,296
627,755
649,057
648,372
682,364
682,364
0
1,808,355
2,051,734
2,051,734
0
0
0
0
0
000002,051,7342,051,7341,808,3550682,364682,364648,372649,057627,755566,296533,082492,373544,198446,719499,437541,589502,613313,476490,800389,914321,692580,302612,169613,706648,9350000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,620
0
0
0
173,768
0
0
0
287,205
0
0
0
331,808
0
0
0
575,515
0
0
633,240
633,240
0
0
1,622,641
1,622,641
0
0
0
0
0
000001,622,6411,622,64100633,240633,24000575,515000331,808000287,205000173,76800070,6200000000000000000000000000
> Total Stockholder Equity
0
693,040
693,040
1,500,653
1,596,238
1,662,507
1,682,267
1,831,277
1,849,945
1,876,768
1,876,768
1,936,921
1,962,506
2,101,262
2,101,262
2,231,612
2,534,163
2,658,123
2,658,123
3,070,151
3,198,391
3,296,203
3,296,203
3,408,203
3,528,399
3,721,481
3,721,481
3,579,042
3,582,689
3,629,079
3,629,079
3,967,400
4,145,026
4,225,554
4,225,554
4,393,764
4,771,872
4,822,119
4,822,119
5,364,941
5,347,090
5,108,392
5,108,392
5,168,166
5,523,609
0
5,523,609
6,329,834
376,915
5,852,832
6,129,938
5,861,818
6,127,078
5,827,166
5,827,166
5,827,1665,827,1666,127,0785,861,8186,129,9385,852,832376,9156,329,8345,523,60905,523,6095,168,1665,108,3925,108,3925,347,0905,364,9414,822,1194,822,1194,771,8724,393,7644,225,5544,225,5544,145,0263,967,4003,629,0793,629,0793,582,6893,579,0423,721,4813,721,4813,528,3993,408,2033,296,2033,296,2033,198,3913,070,1512,658,1232,658,1232,534,1632,231,6122,101,2622,101,2621,962,5061,936,9211,876,7681,876,7681,849,9451,831,2771,682,2671,662,5071,596,2381,500,653693,040693,0400
   Common Stock
0
0
106,532
114,914
114,914
117,882
117,882
117,882
117,882
1,008,237
1,008,237
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
119,604
119,604
1,030,332
1,030,332
1,030,332
1,030,332
1,030,332
119,604
119,604
119,604
1,030,332
119,604
119,604
119,604
1,030,332
119,604
119,604
119,604
119,604119,604119,6041,030,332119,604119,604119,6041,030,332119,604119,604119,6041,030,3321,030,3321,030,3321,030,3321,030,332119,604119,6041,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,030,3321,008,2371,008,237117,882117,882117,882117,882114,914114,914106,53200
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
352,871
352,871
-91,640
549,103
627,074
-10,136
72,410
27,231
614,905
614,905
881,453
822,801
794,134
794,134
1,020,805
1,226,174
1,312,734
1,312,734
1,836,889
1,825,025
1,911,916
1,911,916
2,175,453
2,160,681
2,337,311
2,337,311
2,333,271
2,183,016
2,121,455
2,121,455
2,673,530
2,701,838
2,790,768
2,790,768
3,126,202
3,367,722
3,353,053
3,353,053
4,296,960
4,011,637
3,503,248
3,503,248
4,035,208
4,409,462
0
4,409,462
5,314,614
0
4,984,720
5,053,547
5,046,399
5,252,116
4,949,582
4,949,582
4,949,5824,949,5825,252,1165,046,3995,053,5474,984,72005,314,6144,409,46204,409,4624,035,2083,503,2483,503,2484,011,6374,296,9603,353,0533,353,0533,367,7223,126,2022,790,7682,790,7682,701,8382,673,5302,121,4552,121,4552,183,0162,333,2712,337,3112,337,3112,160,6812,175,4531,911,9161,911,9161,825,0251,836,8891,312,7341,312,7341,226,1741,020,805794,134794,134822,801881,453614,905614,90527,23172,410-10,136627,074549,103-91,640352,871352,8710
   Capital Surplus 0000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
224,656
118,124
938,322
888,428
867,244
888,426
937,642
888,426
-3,060
-3,060
-88,909
-88,909
0
0
-44,360
-61,328
-69,252
-69,252
-58,575
-58,575
-58,575
-58,575
-62,025
-68,710
-68,710
-68,710
-62,422
-62,422
-62,422
-62,422
-55,441
-55,441
-55,441
-55,441
-49,650
-49,584
-49,584
-49,584
-43,770
-43,734
-43,734
-43,734
-164,189
746,539
4,988,419
746,539
-158,761
-376,915
856,774
748,508
-158,692
752,036
757,980
698,665
698,665757,980752,036-158,692748,508856,774-376,915-158,761746,5394,988,419746,539-164,189-43,734-43,734-43,734-43,770-49,584-49,584-49,584-49,650-55,441-55,441-55,441-55,441-62,422-62,422-62,422-62,422-68,710-68,710-68,710-62,025-58,575-58,575-58,575-58,575-69,252-69,252-61,328-44,36000-88,909-88,909-3,060-3,060888,426937,642888,426867,244888,428938,322118,124224,6560



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.